| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
19,740,000 |
| Market
Cap: |
3.82(B) |
| Last
Volume: |
9,322,967 |
Avg
Vol: |
9,296,949 |
| 52
Week Range: |
$120.4 - $312 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Diagnostic Substances |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : 27 |
| Insider 3/6 Months : 27.6 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Madrigal Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Co.'s primary product candidate, resmetirom, is being developed as a once-daily oral pill to treat several disease states, including non-alcoholic steatohepatitis, or NASH. Co. has initiated MAESTRO-NASH, a Phase 3 trial in NASH with its once daily, oral thyroid hormone receptor beta selective agonist, resmetirom. Co. has opened for enrollment MAESTRO-NAFLD-1, a Phase 3 clinical study of patients with biopsy-confirmed or presumed NASH recruited from sites in the U.S.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
424,685 |
424,685 |
424,685 |
| Total Buy Value |
$0 |
$77,751,391 |
$77,751,391 |
$77,751,391 |
| Total People Bought |
0 |
1 |
1 |
1 |
| Total Buy Transactions |
0 |
10 |
10 |
10 |
| Total Shares Sold |
252,542 |
270,142 |
270,142 |
339,631 |
| Total Sell Value |
$62,399,106 |
$66,219,580 |
$66,219,580 |
$85,688,008 |
| Total People Sold |
5 |
7 |
7 |
8 |
| Total Sell Transactions |
13 |
21 |
21 |
26 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Taub Rebecca |
Pres., R&D, and CMO |
• • – |
2024-04-08 |
4 |
AS |
$243.25 |
$658,258 |
D/D |
(2,676) |
458,999 |
|
-22% |
|
| Taub Rebecca |
Pres., R&D, and CMO |
• • – |
2024-04-08 |
4 |
OE |
$9.45 |
$25,288 |
D/D |
2,676 |
461,675 |
|
- |
|
| Friedman Paul A |
|
– • – |
2024-04-08 |
4 |
AS |
$242.95 |
$6,467,491 |
D/D |
(26,270) |
185,735 |
|
-22% |
|
| Friedman Paul A |
|
– • – |
2024-04-08 |
4 |
OE |
$9.45 |
$248,252 |
D/D |
26,270 |
212,005 |
|
- |
|
| Taub Rebecca |
Pres., R&D, and CMO |
• • – |
2024-04-05 |
4 |
AS |
$240.11 |
$6,693,790 |
D/D |
(27,506) |
458,999 |
|
-20% |
|
| Taub Rebecca |
Pres., R&D, and CMO |
• • – |
2024-04-05 |
4 |
OE |
$9.45 |
$259,932 |
D/D |
27,506 |
486,505 |
|
- |
|
| Friedman Paul A |
Director |
– • – |
2024-04-05 |
4 |
AS |
$240.10 |
$6,721,081 |
D/D |
(27,613) |
185,735 |
|
-20% |
|
| Friedman Paul A |
Director |
– • – |
2024-04-05 |
4 |
OE |
$9.45 |
$260,943 |
D/D |
27,613 |
213,348 |
|
- |
|
| Taub Rebecca |
Pres., R&D, and CMO |
• • – |
2024-04-04 |
4 |
AS |
$240.88 |
$4,502,823 |
D/D |
(18,537) |
458,999 |
|
-20% |
|
| Taub Rebecca |
Pres., R&D, and CMO |
• • – |
2024-04-04 |
4 |
OE |
$9.45 |
$175,175 |
D/D |
18,537 |
477,536 |
|
- |
|
| Friedman Paul A |
Director |
– • – |
2024-04-04 |
4 |
AS |
$241.07 |
$4,545,721 |
D/D |
(18,710) |
185,735 |
|
-20% |
|
| Friedman Paul A |
Director |
– • – |
2024-04-04 |
4 |
OE |
$9.45 |
$176,810 |
D/D |
18,710 |
204,445 |
|
- |
|
| Taub Rebecca |
Pres., R&D, and CMO |
• • – |
2024-04-03 |
4 |
AS |
$242.00 |
$6,825,976 |
D/D |
(27,845) |
458,999 |
|
-21% |
|
| Taub Rebecca |
Pres., R&D, and CMO |
• • – |
2024-04-03 |
4 |
OE |
$9.45 |
$263,135 |
D/D |
27,845 |
486,844 |
|
- |
|
| Friedman Paul A |
Director |
– • – |
2024-04-03 |
4 |
AS |
$242.00 |
$6,718,002 |
D/D |
(27,407) |
185,735 |
|
-21% |
|
| Friedman Paul A |
Director |
– • – |
2024-04-03 |
4 |
OE |
$9.45 |
$258,996 |
D/D |
27,407 |
213,142 |
|
- |
|
| Bate Kenneth |
Director |
– • – |
2024-04-02 |
4 |
AS |
$243.28 |
$2,741,219 |
D/D |
(11,212) |
1,198 |
|
-21% |
|
| Bate Kenneth |
Director |
– • – |
2024-04-02 |
4 |
OE |
$105.08 |
$1,178,157 |
D/D |
11,212 |
12,410 |
|
- |
|
| Daly James M |
Director |
– • – |
2024-04-02 |
4 |
AS |
$243.26 |
$2,668,087 |
D/D |
(10,912) |
1,198 |
|
-21% |
|
| Daly James M |
Director |
– • – |
2024-04-02 |
4 |
OE |
$105.08 |
$1,146,633 |
D/D |
10,912 |
12,110 |
|
- |
|
| Bate Kenneth |
Director |
– • – |
2024-04-01 |
4 |
AS |
$255.62 |
$5,473,779 |
D/D |
(21,277) |
1,198 |
|
-24% |
|
| Bate Kenneth |
Director |
– • – |
2024-04-01 |
4 |
OE |
$9.45 |
$1,233,187 |
D/D |
21,277 |
22,475 |
|
- |
|
| Levy Richard S |
|
– • – |
2024-04-01 |
4 |
AS |
$255.90 |
$2,832,335 |
D/D |
(11,000) |
10,298 |
|
-24% |
|
| Levy Richard S |
|
– • – |
2024-04-01 |
4 |
OE |
$7.36 |
$703,160 |
D/D |
11,000 |
21,298 |
|
- |
|
| Daly James M |
Director |
– • – |
2024-04-01 |
4 |
AS |
$255.64 |
$5,550,544 |
D/D |
(21,577) |
1,198 |
|
-24% |
|
413 Records found
|
|
Page 1 of 17 |
|
|
1.05 (0.54%) 
